Literature DB >> 26939931

How trial results are intended to be used: is PRECIS-2 a step forward?

Olaf M Dekkers1, Patrick M Bossuyt2, Jan P Vandenbroucke3.   

Abstract

Mesh:

Year:  2016        PMID: 26939931     DOI: 10.1016/j.jclinepi.2016.01.033

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


× No keyword cloud information.
  6 in total

1.  The application of PRECIS-2 ratings in randomized controlled trials of Chinese herbal medicine.

Authors:  Liming Lu; Li Zhou; Jing Dong; Yu Xiang; Zehuai Wen
Journal:  Oncotarget       Date:  2017-10-31

2.  Framing the conversation: use of PRECIS-2 ratings to advance understanding of pragmatic trial design domains.

Authors:  Paula Darby Lipman; Kirsty Loudon; Leanora Dluzak; Rachael Moloney; Donna Messner; Catherine M Stoney
Journal:  Trials       Date:  2017-11-10       Impact factor: 2.279

3.  A prospective cohort and extended comprehensive-cohort design provided insights about the generalizability of a pragmatic trial: the ProtecT prostate cancer trial.

Authors:  Jenny L Donovan; Grace J Young; Eleanor I Walsh; Chris Metcalfe; J Athene Lane; Richard M Martin; Marta K Tazewell; Michael Davis; Tim J Peters; Emma L Turner; Nicola Mills; Hanan Khazragui; Tarnjit K Khera; David E Neal; Freddie C Hamdy
Journal:  J Clin Epidemiol       Date:  2017-12-27       Impact factor: 6.437

4.  From ideas to studies: how to get ideas and sharpen them into research questions.

Authors:  Jan P Vandenbroucke; Neil Pearce
Journal:  Clin Epidemiol       Date:  2018-03-06       Impact factor: 4.790

Review 5.  Identification of tools used to assess the external validity of randomized controlled trials in reviews: a systematic review of measurement properties.

Authors:  Andres Jung; Julia Balzer; Tobias Braun; Kerstin Luedtke
Journal:  BMC Med Res Methodol       Date:  2022-04-06       Impact factor: 4.615

6.  Real-world evidence: How pragmatic are randomized controlled trials labeled as pragmatic?

Authors:  Rafael Dal-Ré; Perrine Janiaud; John P A Ioannidis
Journal:  BMC Med       Date:  2018-04-03       Impact factor: 8.775

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.